This peptide combination utilizes two complementary pathways to stimulate endogenous growth hormone release. CJC-1295 without DAC acts as a growth hormone–releasing hormone analogue, promoting natural pulsatile GH secretion without prolonged systemic exposure.
Ipamorelin is a selective ghrelin receptor agonist that enhances GH release while maintaining a favorable hormonal profile with minimal impact on cortisol and prolactin levels.
Together, these peptides provide a synergistic and physiologically aligned effect.
Recommended for:
– intensive physical activity programs
– recovery and regeneration support
– age-related decline in growth hormone levels
– body composition optimization
– improvement of sleep quality and vitality
Research and studies:
GHRH and GHRP peptides have been widely studied in sports medicine and aging research. Clinical data indicate that combined use of CJC-1295 without DAC and ipamorelin increases endogenous GH and IGF-1 levels while maintaining a good safety and tolerability profile under controlled use.
Used to stimulate physiological growth hormone secretion, enhance muscle recovery, support metabolic function, improve sleep quality, and promote regenerative processes.
The product is used after reconstitution with a suitable sterile diluent. The administration regimen is determined individually based on intended use and professional guidance.
Contraindications
– hypersensitivity to components
– pregnancy and breastfeeding
– malignant diseases
– severe endocrine disorders
– pediatric and adolescent use
Side effects:
– injection site reactions
– headache
– temporary appetite changes
– fluid retention
